+1-518-621-2074 | US-Canada Toll Free Contact Us

Makers of Stomach Cancer Drugs See Vast Potential in Molecular Heterogeneity of Tumors

about us

Published on : Apr 07, 2020

ResearchMoz.us has announced the addition of a report, titled “Global Stomach Cancer Drugs Market Size, Status and Forecast 2019-2025.”. The report on the global stomach cancer drugs market presents detailed insights into the various growth dynamics, including drug pipelines, regulatory landscape, major clinical trials, and recent research funding.

The study assesses the impacts of various trends on promising clinical avenues in chemotherapy treatments. It also takes a closer look at strategic collaborations by players in prominent regions. Key markets covered in the analysis are the U.S., Europe, Southeast Asia, and Central and South America. 

The stomach cancer drugs market has advanced considerably on the back of growing numbers of anticancer drug components approved by regulatory agencies in various parts of the world. Gastric cancer or stomach cancer has remained as one of the key causes for death from cancer worldwide.

Active adoption of screening technologies in certain developing economies and advent of prognosis techniques around the world have contributed to the rise in incidence of stomach cancer over the past few years. This is a key factor in shaping the demands for anticancer drugs in perioperative and adjuvant chemotherapy in the stomach cancer market.

Researchers Focus on Improving the Outcome of Resectable Gastric Cancer Boosting Market 

A large number of stomach cancer drugs hold potential in second-line chemotherapy. Drug makers are increasingly focusing on unveiling combinations that can improve the outcome of resectable gastric cancer, thereby fueling prospects in the stomach cancer drugs market. Considerable research being carried out by top players for developing biological therapies for select cohorts of patient populations.

These include patients with HER2-positive. Numerous such initiatives have formed a part of clinical trials in the U.S. and Europe. Such research and development activities have been bellwether for growth in the stomach cancer drugs market. 

A favorable regulatory framework in developed countries has promoted drug pipelines in the stomach cancer drugs market. Researchers are in constant search for novel agents for targeting dysfunctional molecular signaling pathways. A number of clinical trials that focus on advanced tumors has adopted this approach. The molecular heterogeneity of gastric tumor presents considerable avenues for contract research organizations and biosimiliar manufacturers. 

The growing need for personalized treatments of patients with aggressive cancer of the stomach, such as gastric carcinoma, has expanded the frontiers in the stomach cancer market. A case in point is approval of pembrolizumab with PD-L1–positive tumors.

Growing Numbers of Randomized Trials in Developed Countries Expand Avenue

In recent years, new avenues have emerged in the stomach cancer drugs market from the some paradigmatic advances made in targeted therapies for treating stomach cancer. Immunotherapy has been one of these advances. In this regard, advent of Chimeric antigen receptor T cell seems to expand the potential for new drugs for stomach cancer, thus boosting the lucrativeness quotient in the market. 

Request a Sample PDF copy with detailed Insights: https://www.researchmoz.us/enquiry.php?type=S&repid=2404838

Growing numbers of randomized trials in developed countries, notably the U.S., have helped in popularizing new drug regimens in the global stomach cancer drugs market. A case in point is three-drug regimen in Europe epirubicin, cisplatin, 5-fluorouracil. 

In the coming few years, metastatic gastric cancer patients might serves as a promising segment for new revenue streams. This might be because of the unmet need. Some of the key players in the stomach cancer drugs market are Jiangsu Hengrui Medicine, Boston Biomedical, Celgene Corporation, Mylan, Taiho Pharmaceutical, Novartis, AstraZeneca, Merck & Co, Kuhnil Pharm, Sanofi S.A., Eli Lilly, and Pfizer.